Suppr超能文献

内在突变 HTT 介导的少突胶质细胞缺陷导致亨廷顿病的髓鞘形成缺陷和行为异常。

Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.

机构信息

Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research (A*STAR), Immunos, 138648 Singapore.

Centre for Molecular Medicine and Therapeutics, BC Children's Hospital Research Institute, University of British Columbia, Vancouver BC V5Z 4H4, Canada.

出版信息

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9622-9627. doi: 10.1073/pnas.1818042116. Epub 2019 Apr 23.

Abstract

White matter abnormalities are a nearly universal pathological feature of neurodegenerative disorders including Huntington disease (HD). A long-held assumption is that this white matter pathology is simply a secondary outcome of the progressive neuronal loss that manifests with advancing disease. Using a mouse model of HD, here we show that white matter and myelination abnormalities are an early disease feature appearing before the manifestation of any behavioral abnormalities or neuronal loss. We further show that selective inactivation of mutant huntingtin (mHTT) in the NG2+ oligodendrocyte progenitor cell population prevented myelin abnormalities and certain behavioral deficits in HD mice. Strikingly, the improvements in behavioral outcomes were seen despite the continued expression of mHTT in nonoligodendroglial cells including neurons, astrocytes, and microglia. Using RNA-seq and ChIP-seq analyses, we implicate a pathogenic mechanism that involves enhancement of polycomb repressive complex 2 (PRC2) activity by mHTT in the intrinsic oligodendroglial dysfunction and myelination deficits observed in HD. Our findings challenge the long-held dogma regarding the etiology of white matter pathology in HD and highlight the contribution of epigenetic mechanisms to the observed intrinsic oligodendroglial dysfunction. Our results further suggest that ameliorating white matter pathology and oligodendroglial dysfunction may be beneficial for HD.

摘要

脑白质异常是包括亨廷顿病(HD)在内的神经退行性疾病的几乎普遍的病理学特征。长期以来的假设是,这种脑白质病理学仅仅是随着疾病进展而出现的进行性神经元丧失的继发结果。在这里,我们使用 HD 的小鼠模型表明,脑白质和髓鞘异常是一种早期疾病特征,出现在任何行为异常或神经元丧失出现之前。我们进一步表明,在 NG2+少突胶质前体细胞群中选择性失活突变型亨廷顿蛋白(mHTT)可防止 HD 小鼠的髓鞘异常和某些行为缺陷。引人注目的是,尽管 mHTT 在包括神经元、星形胶质细胞和小胶质细胞在内的非少突胶质细胞中的持续表达,行为结果的改善仍然存在。通过 RNA-seq 和 ChIP-seq 分析,我们发现一种致病机制涉及 mHTT 增强多梳抑制复合物 2(PRC2)的活性,这与 HD 中观察到的内在少突胶质细胞功能障碍和髓鞘缺陷有关。我们的发现挑战了关于 HD 脑白质病理学病因的长期教条,并强调了表观遗传机制对观察到的内在少突胶质细胞功能障碍的贡献。我们的结果进一步表明,改善脑白质病理学和少突胶质细胞功能障碍可能对 HD 有益。

相似文献

9

引用本文的文献

3
The role of oligodendroglial dysfunction in Huntington's disease.少突胶质细胞功能障碍在亨廷顿舞蹈病中的作用。
J Huntingtons Dis. 2025 Aug;14(3):270-278. doi: 10.1177/18796397251358017. Epub 2025 Aug 7.

本文引用的文献

8
Targeting EZH2 in cancer.在癌症中靶向EZH2
Nat Med. 2016 Feb;22(2):128-34. doi: 10.1038/nm.4036.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验